The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Open accessAbstract
Abnormal expression of activating/inhibitory receptors leads to natural killer (NK) cells dysfunction in tumor. Here we show that programmed cell death protein 1 (PD-1), a well-known immune checkpoint of T cells, is highly expressed on peripheral and tumor-infiltrating NK cells from patients with digestive cancers including esophageal, liver, colorectal, gastric and biliary cancer. The increased PD-1 expression on NK cells indicates poorer survival in esophageal and liver cancers. Blocking PD-1/PD-L1 signaling markedly enhances cytokines production and degranulation and suppresses apoptosis of NK cells in vitro. PD-1/PD-L1 exerts inhibitory effect through repressing the activation of PI3K/AKT signaling in NK cells. More importantly, a PD-1 blocking antibody was found to significantly suppress the growth of xenografts in nude mice, and this inhibition of tumor growth was completely abrogated by NK depletion. These findings strongly suggested that PD-1 is an inhibitory regulator of NK cells in digestive cancers. PD-1 blockade might be an efficient strategy in NK cell-based tumor immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Functions of natural killer cells
Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection
Petrovas, C., Casazza, J. P., Brenchley, J. M., Price, D. A., Gostick, E., Adams, W. C., Precopio, M. L., Schacker, T., Roederer, M., Douek, D. C., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061496 · Cited by 889
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Blank, C., Gajewski, T. F., & Mackensen, A. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0593-x · Cited by 637
Liver-resident NK cells confer adaptive immunity in skin-contact inflammation
Peng, H., Jiang, X., Chen, Y., Sojka, D. K., Wei, H., Gao, X., Sun, R., Yokoyama, W. M., & Tian, Z. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66381 · Cited by 545
Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513
Li, H., Wu, K., Tao, K., Chen, L., Zheng, Q., Lu, X., Liu, J., Shi, L., Liu, C., Wang, G., et al. (2012) · Hepatology · doi:10.1002/hep.25777 · Cited by 496
Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.025 · Cited by 465
CIS is a potent checkpoint in NK cell–mediated tumor immunity
Delconte, R. B., Kolesnik, T. B., Dagley, L. F., Rautela, J., Shi, W., Putz, E. M., Stannard, K., Zhang, J.-G., Teh, C., Firth, M., et al. (2016) · Nature Immunology · doi:10.1038/ni.3470 · Cited by 384
PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor
Shi, L., Chen, L., Wu, C., Zhu, Y., Xu, B., Zheng, X., Sun, M., Wen, W., Dai, X., Yang, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1352 · Cited by 312
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Beldi-Ferchiou, A., Lambert, M., Dogniaux, S., Vély, F., Vivier, E., Olive, D., Dupuy, S., Levasseur, F., Zucman, D., Lebbé, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12150 · Cited by 312
Tim-3 fosters HCC development by enhancing TGF-β-mediated alternative activation of macrophages
Yan, W., Liu, X., Ma, H., Zhang, H., Song, X., Gao, L., Liang, X., & Ma, C. (2015) · Gut · doi:10.1136/gutjnl-2014-307671 · Cited by 306
Self-citationThe tumor microenvironment in esophageal cancer
Lin, E. W., Karakasheva, T. A., Hicks, P. D., Bass, A. J., & Rustgi, A. K. (2016) · Oncogene · doi:10.1038/onc.2016.34 · Cited by 303
Li, Y., Liang, L., Dai, W., Cai, G., Xu, Y., Li, X., Li, Q., & Cai, S. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0539-x · Cited by 270
Self-citationWu, Y., Kuang, D.-M., Pan, W.-D., Wan, Y.-L., Lao, X.-M., Wang, D., Li, X.-F., & Zheng, L. (2013) · Hepatology · doi:10.1002/hep.26192 · Cited by 266
Dual Roles for Immunity in Gastrointestinal Cancers
Ferrone, C., & Dranoff, G. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.27.9992 · Cited by 241
IL-15–PI3K–AKT–mTOR: A Critical Pathway in the Life Journey of Natural Killer Cells
Ali, A. K., Nandagopal, N., & Lee, S. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00355 · Cited by 153
Ma, C., Patel, K., Singhi, A. D., Ren, B., Zhu, B., Shaikh, F. Y., & Sun, W. (2016) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000698 · Cited by 150
Self-citationWiesmayr, S., Webber, S. A., Macedo, C., Popescu, I., Smith, L., Luce, J., & Metes, D. (2011) · European Journal of Immunology · doi:10.1002/eji.201141832 · Cited by 118
Manipulating the PD-1 pathway to improve immunity
Kamphorst, A. O., & Ahmed, R. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.003 · Cited by 117
PD-1 Expression on Natural Killer Cells and CD8 + T Cells During Chronic HIV-1 Infection
Norris, S., Coleman, A., Kuri-Cervantes, L., Bower, M., Nelson, M. R., & Goodier, M. R. (2012) · Viral Immunology · doi:10.1089/vim.2011.0096 · Cited by 117
Monitoring immune responses in the tumor microenvironment
Wargo, J. A., Reddy, S. M., Reuben, A., & Sharma, P. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.006 · Cited by 117
Golden‐Mason, L., Klarquist, J. S., Wahed, A. S., & Rosen, H. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3637 · Cited by 112
Giannelli, G., Rani, B., Dituri, F., Cao, Y., & Palasciano, G. (2014) · Gut · doi:10.1136/gutjnl-2014-307323 · Cited by 112
The PD-1/B7-H1 Pathway Modulates the Natural Killer Cells versus Mouse Glioma Stem Cells
Huang, B. Y., Zhan, Y. P., Zong, W. J., Yu, C. J., Li, J., Qu, Y. M., & Han, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134715 · Cited by 110
Chen, K., Cheng, G., Zhang, F., Zhang, N., Li, D., Jin, J., Wu, J., Ying, L., Mao, W., & Su, D. (2016) · Oncotarget · doi:10.18632/oncotarget.8956 · Cited by 110
Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer
Saito, H., Kuroda, H., Matsunaga, T., Osaki, T., & Ikeguchi, M. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23281 · Cited by 94
Toh, J. W. T., SOUZA, P. D., Lim, S. H.-S., Singh, P., Chua, W. M., Ng, W. L., & Spring, K. J. (2016) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2016.07.007 · Cited by 85
Hassan, S. S., Akram, M., King, E. C., Dockrell, H. M., & Cliff, J. M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137646 · Cited by 72
Specific CD8+T cell response immunotherapy for hepatocellular carcinoma and viral hepatitis
Moreno-Cubero, E., & Larrubia, J. R. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6469 · Cited by 61
Immunosenescence: limitations of natural killer cell-based cancer immunotherapy
Tarazona, R., Sánchez-Correa, B., Casas-Avilés, I., Campos, C., Pera, A., Morgado, S., López-Sejas, N., Hassouneh, F., Bergua, J., Arcos, M. J., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1882-x · Cited by 56
Zhang, G., Liu, W., Zhang, L., Wang, J., Kuang, M.-H., Liu, P., Lin, Y., Dai, S., & Du, J. (2011) · Clinical and Developmental Immunology · doi:10.1155/2011/384726 · Cited by 51
Chen, Y., Chen, B., Yang, T., Xiao, W., Qian, L., Ding, Y., Ming-chun, J., Ge, X., & Gong, W. (2015) · Cellular and Molecular Immunology · doi:10.1038/cmi.2015.81 · Cited by 51
Chen, Y., Wu, S., Guo, G., Fei, L., Guo, S. J., Yang, C., Fu, X., & Wu, Y. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001347 · Cited by 47
Watanabe, M., Kono, K., Kawaguchi, Y., Mizukami, Y., Mimura, K., Maruyama, T., Izawa, S., & Fujii, H. (2010) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2010.01073.x · Cited by 42
Solaymani-Mohammadi, S., Lakhdari, O., Minev, I., Shenouda, S., Frey, B. F., Billeskov, R., Singer, S. M., Berzofsky, J. A., Eckmann, L., & Kagnoff, M. F. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.4a0115-003rr · Cited by 25
Natural killer cell maturation markers in the human liver and expansion of an NKG2C+KIR+ population
Hydes, T., Abuhilal, M., Armstrong, T., Primrose, J., Takhar, A., & Khakoo, S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60360-9 · Cited by 23
Bücklein, V., Adunka, T., Mendler, A. N., Issels, R. D., Subklewe, M. S., Schmollinger, J. C., & Noeßner, E. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1178421 · Cited by 22
Zhang, L., Song, X., Mohri, Y., & Qiao, L. (2015) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x09666140812112305 · Cited by 11
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Exploring the NK cell platform for cancer immunotherapy
Myers, J. A., & Miller, J. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0426-7 · Cited by 1,276
Natural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99317 · Cited by 817
The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma
Donne, R., & Lujambio, A. (2023) · Hepatology · doi:10.1002/hep.32740 · Cited by 631
Metadata
- Authors
- Liu, Y., Cheng, Y., Xu, Y., Wang, Z., Du, X., Li, C., Peng, J., Gao, L., Liang, X., & Ma, C.
- Venue
- Oncogene
- Published
- 2017-07-10
- Volume
- 36
- Issue
- 44
- Pages
- 6143-6153
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2735041159
- Cited by
- 366
- References
- 49
- FWCI
- 13.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.